Last week we announced the TGA approval for Cell Therapies to manufacture Novartis’ CAR-T therapy, Kymriah® (tisagenlecleucel) in Melbourne, Australia. Take a behind-the-scenes look into the hard work and collaboration required to achieve this important milestone.
Cell Therapies team members featured in this video:
– A/Prof Dominic Wall, Interim CEO and Chief Scientific Officer
– Fran Harding, Cell Therapies Specialist
– Carmen Chong, Quality Control Analyst
– Ayse Mouminoglu, Quality Assurance Manager